3rd Circ. To Review Venue Ruling In GSK Birth Defects Case

Law360, New York (January 27, 2014, 2:52 PM EST) -- The Third Circuit agreed Friday to allow plaintiffs in a suit alleging GlaxoSmithKline PLC's antidepressant drug Paxil caused birth defects to appeal the company's removal of the case to federal court more than a year after the suit began.

Earlier this month, GSK challenged the plaintiffs' Dec. 23 petition for permission to appeal the company's removal of the case to federal court following a landmark Third Circuit ruling in June keeping a separate suit over GSK's morning-sickness drug thalidomide in federal court.

The company argued that...
To view the full article, register now.